Margaret Burroughs Selected Research

P-300

8/2019	Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
4/2018	Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
4/2018	Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
1/2018	Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Margaret Burroughs Research Topics

Disease

16	Infections 01/2021 - 03/2011
15	Fibrosis (Cirrhosis) 04/2022 - 05/2009
10	Chronic Hepatitis C 01/2021 - 02/2011
5	Hepatitis C 04/2022 - 05/2009
2	Portal Hypertension 04/2022 - 06/2011
2	Anemia 01/2017 - 03/2011
1	Liver Diseases (Liver Disease) 01/2021
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2020
1	Virus Diseases (Viral Diseases) 01/2020
1	Nasopharyngitis 01/2017
1	Dysgeusia (Parageusia) 05/2014
1	Hepatitis 07/2013
1	Varicose Veins (Varicose Vein) 06/2011
1	Disease Progression 06/2011
1	Hepatocellular Carcinoma (Hepatoma) 06/2011
1	Persistent Infection 03/2011

Drug/Important Bio-Agent (IBA)

13	glecaprevir and pibrentasvirIBA 04/2022 - 01/2018
10	Ribavirin (Virazole)FDA LinkGeneric 01/2020 - 05/2009
6	peginterferon alfa-2b (Pegintron)FDA Link 05/2014 - 05/2009
5	Antiviral Agents (Antivirals)IBA 01/2020 - 07/2013
5	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 05/2014 - 03/2011
4	InterferonsIBA 01/2020 - 06/2011
4	P-300IBA 08/2019 - 01/2018
4	paritaprevirIBA 04/2018 - 10/2015
4	ombitasvirIBA 04/2018 - 10/2015
3	pibrentasvirIBA 01/2020 - 01/2018
3	glecaprevirIBA 01/2020 - 01/2018
3	Ritonavir (Norvir)FDA Link 04/2018 - 10/2015
3	Protease Inhibitors (Protease Inhibitor)IBA 01/2018 - 07/2013
3	Interferon-alpha (Interferon Alfa)IBA 06/2011 - 05/2009
2	Pharmaceutical PreparationsIBA 01/2020 - 10/2015
2	Proteins (Proteins, Gene)FDA Link 01/2018 - 07/2013
2	RNA (Ribonucleic Acid)IBA 10/2015 - 05/2009
1	TabletsIBA 01/2020
1	BilirubinIBA 01/2017
1	Serine Proteinase Inhibitors (Serine Protease Inhibitors)IBA 09/2013
1	Peptide Hydrolases (Proteases)FDA Link 07/2013
1	Erythropoietin FDA Link 03/2011

Therapy/Procedure

7	Therapeutics 04/2022 - 05/2009
2	Retreatment 03/2013 - 03/2011
1	Duration of Therapy 01/2018